MolNFT v1 · #48221 · protein
Crystal structure of PFPK7 in complex with an ATP-site inhibitor
2PMN · SER/THR protein kinase, putative: “Crystal structure of PFPK7 in complex with an ATP-site inhibitor”. X-ray diffraction, 1 ligand (K51), 4 pockets (best druggability 0.68). MolNFT v1 #48221 on GenesisL1: 3D structure, binding sites…
- PDB
- 2PMN
- Type
- protein
- Length
- 340 residues
- Chains
- 1
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- SER/THR protein kinase, putative
- UniProt
- Q7YTF7
- Ligands
- K51
- Pockets
- 4 · best druggability 0.68
Structure
x-ray diffraction · 1 distinct chain · 32% helix, 22% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| X | SER/THR protein kinase, putative | protein | 340 | 32% helix, 22% strand | Q7YTF7 |
Ligands and binding sites
- K51 · 4-(6-{[(1S)-1-(hydroxymethyl)-2-methylpropyl]amino}imidazo[1,2-b]pyridazin-3-yl)benzonitrile · ligand · chains X
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
4 pockets found on a 1 Å grid, 1 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 438 | 0.68 | 0.79 | 48 | K51 |
| 2 | 199 | 0.43 | 0.73 | 24 | empty |
| 3 | 98 | 0.42 | 0.78 | 15 | empty |
| 4 | 90 | 0.39 | 0.76 | 19 | empty |
Compared structures
- 2PMN · Crystal structure of PfPK7 in complex with an ATP-site inhibitor · the same entry in another collection · chain X against X, TM-score 1.00
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt Q7YTF7
- Elsewhere: RCSB PDB 2PMN · PDBe 2PMN · UniProt Q7YTF7
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.